% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Sabri:902739,
author = {Sabri, Osama and Meyer, Philipp M and Gräf, Susanne and
Hesse, Swen and Wilke, Stephan and Becker, Georg-Alexander
and Rullmann, Michael and Patt, Marianne and Luthardt, Julia
and Wagenknecht, Gudrun and Hoepping, Alexander and Smits,
Rene and Franke, Annegret and Sattler, Bernhard and Tiepolt,
Solveig and Fischer, Steffen and Deuther-Conrad, Winnie and
Hegerl, Ulrich and Barthel, Henryk and Schönknecht, Peter
and Brust, Peter},
title = {{C}ognitive correlates of α4β2 nicotinic acetylcholine
receptors in mild {A}lzheimer’s dementia},
journal = {Brain},
volume = {141},
number = {6},
issn = {0006-8950},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {FZJ-2021-04521},
pages = {1840 - 1854},
year = {2018},
abstract = {In early Alzheimer’s dementia, there is a need for PET
biomarkers of disease progression with close associations to
cognitive dysfunction that may aid to predict further
cognitive decline and neurodegeneration. Amyloid biomarkers
are not suitable for that purpose. The α4β2 nicotinic
acetylcholine receptors (α4β2-nAChRs) are widely abundant
in the human brain. As neuromodulators they play an
important role in cognitive functions such as attention,
learning and memory. Post-mortem studies reported lower
expression of α4β2-nAChRs in more advanced Alzheimer’s
dementia. However, there is ongoing controversy whether
α4β2-nAChRs are reduced in early Alzheimer’s dementia.
Therefore, using the recently developed
α4β2-nAChR-specific radioligand (−)-18F-flubatine and
PET, we aimed to quantify the α4β2-nAChR availability and
its relationship to specific cognitive dysfunction in mild
Alzheimer’s dementia. Fourteen non-smoking patients with
mild Alzheimer’s dementia, drug-naïve for cholinesterase
therapy, were compared with 15 non-smoking healthy controls
matched for age, sex and education by applying
(−)-18F-flubatine PET together with a neuropsychological
test battery. The one-tissue compartment model and Logan
plot method with arterial input function were used for
kinetic analysis to obtain the total distribution volume
(VT) as the primary, and the specific binding part of the
distribution volume (VS) as the secondary quantitative
outcome measure of α4β2-nAChR availability. VS was
determined by using a pseudo-reference region. Correlations
between VT within relevant brain regions and Z-scores of
five cognitive functions (episodic memory, executive
function/working memory, attention, language, visuospatial
function) were calculated. VT (and VS) were applied for
between-group comparisons. Volume of interest and
statistical parametric mapping analyses were carried out.
Analyses revealed that in patients with mild Alzheimer’s
dementia compared to healthy controls, there was
significantly lower VT, especially within the hippocampus,
fronto-temporal cortices, and basal forebrain, which was
similar to comparisons of VS. VT decline in Alzheimer’s
dementia was associated with distinct domains of impaired
cognitive functioning, especially episodic memory and
executive function/working memory. Using (−)-18F-flubatine
PET in patients with mild Alzheimer’s dementia, we show
for the first time a cholinergic α4β2-nAChR deficiency
mainly present within the basal forebrain-cortical and
septohippocampal cholinergic projections and a relationship
between lower α4β2-nAChR availability and impairment of
distinct cognitive domains, notably episodic memory and
executive function/working memory. This shows the potential
of (−)-18F-flubatine as PET biomarker of cholinergic
α4β2-nAChR dysfunction and specific cognitive decline.
Thus, if validated by longitudinal PET studies,
(−)-18F-flubatine might become a PET biomarker of
progression of neurodegeneration in Alzheimer’s dementia.},
cin = {ZEA-2},
ddc = {610},
cid = {I:(DE-Juel1)ZEA-2-20090406},
pnm = {5253 - Neuroimaging (POF4-525) / BMBF-01EZ0822 -
NorChloro-Fluoro HomoEpiBatidin (NCFHEB) ein potentieller
Positronen-Emission Tomographie-(PET) Marker der frühen
Alzheimer-Demenz (BMBF-01EZ0822)},
pid = {G:(DE-HGF)POF4-5253 / G:(DE-Juel1)BMBF-01EZ0822},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29672680},
UT = {WOS:000434113500030},
doi = {10.1093/brain/awy099},
url = {https://juser.fz-juelich.de/record/902739},
}